Abraham S. Kanate

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy

Abraham S. Kanate, Navneet S. Majhail, Bipin N. Savani et al. · Biology of Blood and Marrow Transplantation · 2020 · 274 citations · Full text

Medicine, Hematology, Immunology +17

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors

Abraham S. Kanate, Alberto Mussetti, Mohamed A. Kharfan‐Dabaja et al. · Blood · 2015 · 271 citations · Full text

Medicine, Hematology, Immunology +15

PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD

Bradley M. Haverkos, Diana Abbott, Mehdi Hamadani et al. · Blood · 2017 · 242 citations · Full text

Medicine, Hematology, Oncology +17

Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy

Mohamed A. Kharfan‐Dabaja, Ambuj Kumar, Ernesto Ayala et al. · Transplantation and Cellular Therapy · 2021 · 181 citations · Full text

Medicine, Hematology, Immunology +16